Click here for slides on this topic


Hypertension

A condition in which the blood pressure in the arteries is elevated. Primary hypertension refers to elevated blood pressure with no underlying causes; often referred to as essential hypertension. Secondary hypertension is caused by other conditions.


The following content matched the glossary term: Hypertension

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Top

Tikkanen I, Narko K, Zeller C, et al; for the EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014;Epub ahead of print. DOI: 10.2337/dc14-1096.

Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study

Top

Cheng S, Claggett B, Correia AW, et al. Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study. Circulation. 2014;130:820-828.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Older Adults

Top

Recommendations for older adults with diabetes from the 2016 ADA guidelines

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Hypertension Slides Found: 173
Prevalence of the Insulin Resistance Syndrome (NCEP) in the US Population
Hypertension and Glucose Tolerance in Four Ethnic Groups
Diabetes and Post-MI Survival in Two Ethnic Groups
Increased Fructose Consumption and the Rise in Obesity
Assessing Risk: BMI and Waist Circumference
Assessing Risk for Morbidity and Mortality: Comorbidities and Other Risk Factors
Effect of Diet and Exercise on Inflammatory Markers
UKPDS Results: Tight BP Control
Hypertension JNC 7
Hypertension Management JNC 7
Hypertension Management JNC 7 (con't)
IRAS: Number of CVD Risk Factors and Conversion to Type 2 Diabetes
Effect of 4 Diets on Weight Loss and Cardiac Risk Factors
HF in Women >=65 Yr Old Strongly Associated With Preserved LVSF
ALLHAT: Clinical Outcomes in Antihypertensive Treatments
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
Compelling Indications for Hypertension Drug Classes
LIFE: New-Onset Diabetes
ISHIB Recommendations for African-Americans With High BP
CVD Risk Reduction From Tight Control of BP and Glucose in Type 2 Diabetes
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
Recommended Treatment of Hypertension in Diabetes
Compelling Indications for Hypertension Drug Classes (1 of 2)
Diabetes and Hypertension
ACCORD: Study Design
ADVANCE Substudy: Effects of BP Lowering and Intensive Glucose Control on Retinopathy
LOADD: Nutritional Intervention for Persistent, Treated Hyperglycemia
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
High-Normal A1C as a Type 2 Diabetes Predictor: Design
High-Normal A1C as a Type 2 Diabetes Predictor: Results
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
ARIC: Role of A1C in Predicting Hypertension—Design
ARIC: Role of A1C in Predicting Hypertension—Results
Health Consequences of Obesity
Medical Comorbidities Associated with Obesity
Association Between Obesity and Comorbidities
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Long-term Change in BMI After Roux-en-Y Gastric Bypass
JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor*
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
NHANES: Prevalence of Hypertension Awareness and Treatment Among US Adults
NHANES: Hypertension Prevalence Among US Adults, 2003-2010
NHANES: Uncontrolled Hypertension Prevalence by Selected Parameters in US Adults With Hypertension, 2003-2010
NHANES: Prevalence of Awareness and Treatment of Uncontrolled Hypertension by Selected Parameters in US Adults With Hypertension, 2003-2010
Key Facts: Awareness and Treatment of Uncontrolled Hypertension in US Adults, NHANES 2003-2010
RYGB Surgery: Long-Term Health-Related Outcomes Design
RYGB Surgery: Incidence of Hypertension, Dyslipidemia Values at 6 Years
RYGB Surgery: Remission of Hypertension, Dyslipidemia Values at 6 Years
Comorbidities in Children and Adolescents With Type 2 Diabetes: Hypertension
Effect of Early Hypertension Control on CV Events in Diabetes: Design
Effect of Early Hypertension Control on CV Events in Diabetes: Results
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
ESH/ESC Hypertension Guidelines: Classification of BP Levels
ESH/ESC Hypertension Guidelines: CV Risk Stratification
ESH/ESC Hypertension Guidelines: Individuals at Higher CV Risk
ESH/ESC Hypertension Guidelines: Diagnostic Evaluation
ESH/ESC Hypertension Guidelines: Medical History
ESH/ESC Hypertension Guidelines: Physical Examination
ESH/ESC Hypertension Guidelines: Laboratory Tests
ESH/ESC Hypertension Guidelines: Lifestyle, Antihypertensive Therapy for High Normal BP
ESH/ESC Hypertension Guidelines: Lifestyle, Antihypertensive Therapy for Grade 1 HTN
ESH/ESC Hypertension Guidelines: Lifestyle, Antihypertensive Therapy for Grade 2 HTN
ESH/ESC Hypertension Guidelines: Lifestyle, Antihypertensive Therapy for Grade 3 HTN
ESH/ESC Hypertension Guidelines: BP Goals for Hypertensive Patients
ESH/ESC Hypertension Guidelines: Lifestyle Changes for Hypertensive Patients
ESH/ESC Hypertension Guidelines: Compelling Indications for Hypertension Treatment
ESH/ESC Hypertension Guidelines: Preferred Hypertension Treatment for Unique Circumstances
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Clinical CV Event
ESH/ESC Hypertension Guidelines: Hypertension Treatment Options
ESH/ESC Hypertension Guidelines: Treatment for Masked and White-Coat Hypertension
ESH/ESC Hypertension Guidelines: Hypertension Treatment in the Elderly
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Women
ESH/ESC Hypertension Guidelines: Hypertension Treatment for People With Diabetes
ESH/ESC Hypertension Guidelines: Hypertension Treatment for People With Metabolic Syndrome
nbESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Nephropathy
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Cerebrovascular Disease
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Heart Disease
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Atherosclerosis, Arteriosclerosis, and PAD
ESH/ESC Hypertension Guidelines: Treatment for Patients With Resistant Hypertension
ESH/ESC Hypertension Guidelines: Treatment of Risk Factors Associated With Hypertension
Diabetes Surgery Study: Greater Number of Subjects Achieved Primary Endpoint with Gastric Bypass Vs Lifestyle & Medical Management
Diabetes Surgery Study: Fewer Medications, Greater Weight Change with Gastric Bypass
Diabetes Surgery Study: Design
SAVOR-TIMI 53: Design
ADA Nutrition Guidelines: Eating Patterns
LABS-2: 3-Yr Weight Loss After Bariatric Surgery
LABS-2: 3-Yr Mortality After Bariatric Surgery
LABS-2: 3-Yr Remission & Incidence of Cardiometabolic Outcomes After Bariatric Surgery
Teen-LABS: Rates of Complications 30 Days After Bariatric Surgery
ADA Nutrition Guidelines: Sodium
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Outcomes
AHA/ACC/TOS Obesity Guidelines: Predictors of Weight Loss With Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Assessing BMI & Determining Readiness for Lifestyle Changes
AHA/ACC/TOS Obesity Guidelines: Treatment Algorithm for Overweight & Obese Adults Committed to Weight Loss
SEQUEL Subanalysis: Design
ACC AHA Lifestyle Management Guidelines Sodium BP | NDEI
Physical Activity Blood Pressure Lipids ACC AHA Lifestyle Guideline | NDEI
Diabetes Cognitive Dysfunction | NDEI
JNC 8 Guidelines BP Treatment Adults Over 60 PPT | NDEI
JNC 8 Guidelines BP Treatment Goal Adults Under Age 60 PPT | NDEI
BP Treatment Goal for Adults With CKD JNC 8 Guidelines PPT | NDEI
BP Treatment Threshold & Goal in Adults Aged Greater Than or Equal to 18 Years With Diabetes | NDEI
Therapy Initiation & Goals for Blood Pressure | NDEI
JNC 8 Hypertension Treatment Algorithm Guidelines PPT | NDEI
JNC 8 Hypertension Treatment Algorithm Adults With Diabetes or CKD | NDEI
JNC 8 Guidelines SBP Target Adults Over Age 60 PPT | NDEI
JNC 8 Implications of SBP Goal Adults Over Age 60 PPT | NDEI
JNC 8 Age 60 Cut Point for Less Aggressive BP Treatment | NDEI
Evidence for Lower SBP Target for Older Adults JNC 8 Guidelines | NDEI
SBP Target 140 in Adults Over Age 60 JNC 8 Guidelines PPT | NDEI
JNC 8 Hypertension Guidelines 2014 PPT | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy PPT | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy for Black Patients | NDEI
JNC 8 Guidelines Treatment Hypertension CKD PPT | NDEI
Antihypertensive Therapy to Achieve Goal BP JNC 8 PPT | NDEI
Antihypertensive Therapy Dosing Strategies | NDEI
JNC 8 SBP Goal Older Adults Disagreement PPT | NDEI
SHEP & HYVET Results Consistent With Epidemiologic Data JNC 8 | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Diabetes Pregnancy Guidelines Preconception Hypertension | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Diabetes Macrovascular Complications US Adults 2012 | NDEI
ARIC Cardiovascular Risk Trends | NDEI
Hypertension Obesity Diabetes CVD Risk Factors in ARIC Study | NDEI
CVD Risk Trends ARIC Gender | NDEI
Trends in CVD Risk ARIC Study | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
CVD Risk Trends By Race ARIC Study | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
Teen-LABS CVD Risk in Adolescents Undergoing Bariatric Surgery | NDEI
Effect of Bariatric Surgery on Type 2 Diabetes Medication Use | NDEI
Safety Bariatric Surgery for BMI <35 at 1 Year
US Adults Who May Be Candidates for Obesity Therapy | NDEI
Phentermine + Topiramate A1C Targets Obese Subjects With Type 2 Diabetes | NDEI
Phentermine + Topiramate Decreases Need for Antidiabetic Treatments CONQUER | NDEI
Phentermine + Topiramate Safety Obesity Type 2 Diabetes | NDEI PPT
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
EMPA-REG Blood Pressure Reductions With Empagliflozin SGLT2 | NDEI PPT
EMPA-REG A1C & Weight Loss Empagliflozin SGLT2 Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
EMPA-REG BP: A1C, BP, & Weight Reduction With Empagliflozin in Type 2 Diabetes & Hypertension Clinical Significance for HCPs
ADA Type 1 Diabetes Guidelines Children and Adolescent Treatment | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
Treatment Strategies for Long-Term Weight Loss ENDO Obesity Guidelines | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
AACE 2015 Guidelines Managing Dyslipidemia in Diabetes PPT | NDEI
AACE 2015 Guidelines Hypertension Management PPT | NDEI
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
ACCORD BP Post-hoc Analysis: Design
Type 2 Diabetes Risk Factors US Preventive Services Guidelines | NDEI
Type 2 Diabetes and Prediabetes Screening for Children ADA Guidelines | NDEI
Diabetes Comorbities ADA Guidelines | NDEI PPT
Fatty Liver Disease Is A Diabetes Comorbidity ADA Guidelines | NDEI
Sleep Apnea Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cancer Is A Diabetes Comorbidity ADA Guidelines | NDEI PPT
Fractures Are A Diabetes Comorbidity ADA Guidelines | NDEI
Low Testosterone Is A Comorbidity of Diabetes ADA Guidelines | NDEI
Hearing Impairment Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cognitive Impairment & Diabetes ADA Guidelines Slide | NDEI
Physical Activity Recommendations 2016 ADA Diabetes Guidelines | NDEI
Hypertension Treatment Options in Diabetes ADA Guidelines | NDEI PPT
Lifestyle Changes for Hypertension in Diabetes ADA Guidelines | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Antiplatelet Therapy Recommendations ADA Guidelines | NDEI PPT
2016 ADA Guidelines for Treating Hypertension in Children With Type 1 Diabetes | NDEI
Managing Hypertension During Pregnancy ADA Guidelines | NDEI PPT
Blood Pressure Treatment Targets in Diabetes ADA Guidelines | NDEI PPT
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
ACCELERATE Evacetrapib Doubles HDL-C & Lowers LDL-C CETP | NDEI